HC Wainwright Brokers Decrease Earnings Estimates for RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities researchers at HC Wainwright cut their FY2025 EPS estimates for Rhythm Pharmaceuticals in a report released on Sunday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($3.09) per share for the year, down from their prior estimate of ($2.86). HC Wainwright currently has a “Buy” rating and a $110.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.73) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($2.03) EPS.

Other equities research analysts have also issued research reports about the stock. Guggenheim increased their price objective on shares of Rhythm Pharmaceuticals from $119.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Oppenheimer lowered shares of Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 5th. JMP Securities boosted their price objective on shares of Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a “market outperform” rating in a research report on Thursday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group lowered their target price on Rhythm Pharmaceuticals from $157.00 to $139.00 and set a “buy” rating for the company in a research note on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Rhythm Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $113.23.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ:RYTM opened at $99.86 on Wednesday. The business has a fifty day moving average of $102.80 and a 200-day moving average of $85.56. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $116.00. The firm has a market cap of $6.66 billion, a PE ratio of -33.18 and a beta of 2.12.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.10). The business had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.71 million. Rhythm Pharmaceuticals had a negative net margin of 117.13% and a negative return on equity of 1,831.43%.

Institutional Trading of Rhythm Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of RYTM. Mirae Asset Global Investments Co. Ltd. boosted its stake in Rhythm Pharmaceuticals by 4.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock worth $259,000 after acquiring an additional 110 shares during the last quarter. Captrust Financial Advisors increased its position in shares of Rhythm Pharmaceuticals by 0.7% in the 2nd quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock valued at $1,104,000 after buying an additional 114 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after buying an additional 141 shares in the last quarter. Optiver Holding B.V. lifted its holdings in Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after acquiring an additional 144 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in Rhythm Pharmaceuticals by 1.0% in the first quarter. Victory Capital Management Inc. now owns 17,326 shares of the company’s stock valued at $918,000 after acquiring an additional 174 shares during the period.

Insider Activity at Rhythm Pharmaceuticals

In related news, insider Joseph Shulman sold 9,748 shares of the company’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $115.24, for a total value of $1,123,359.52. Following the completion of the sale, the insider owned 8,509 shares in the company, valued at approximately $980,577.16. This represents a 53.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold 31,188 shares of company stock worth $3,483,583 over the last ninety days. 6.10% of the stock is owned by insiders.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.